CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
High ImpactOriginal article

FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues

RegulatoryrejectedNegative
AI Analysis

Summary

The FDA rejected ITM Isotope Technologies' advanced cancer radiopharma therapy due to manufacturing concerns. The company plans to resubmit the application after addressing the agency's issues.

Outcome Details

FDA rejected radiopharma therapy over manufacturing issues

Importance:8/10
Sentiment:
-0.80
FDA rejectionmanufacturingradiopharmaresubmission

Read the original article

Published by BioSpace on August 11, 2026 1:55 PM

Read Original